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as therapeutics, imaging agents, genes, and proteins.Hitting the Target
While bacteriophage can be employed to deliver DNAwith Bifunctional Phage to mammalian cells, problems are encountered when
using the phage particles for delivery of other reagents
[18]. Like antibodies, bacteriophage are large and diffi-
cult to modify in a regiospecific fashion. Often, chemical
coupling of small molecules or proteins to the surface
of a phage results in loss of binding to the cellular target,Peptide libraries are rich sources of cell-targeting pep-
tides. In this issue of Chemistry & Biology, Pasqualini the formation of phage aggregates, and/or a decrease
and coworkers have developed a chimeric cell-tar- in the ability of the phage to infect E. coli. For these
geting phage system that can easily be modified to reasons, efforts have been placed on translating the
delivery of a variety of reagents without need for chem- peptide responsible for cell targeting out of the context
ical conjugation [1]. of the phage particle itself, while retaining the peptide’s
affinity and cell-targeting abilities. The resulting syn-
thetic peptide constructs have been used to deliver small
Despite the fact that Paul Ehrlich introduced the concept molecules into cells, and adenovirus particles have been
of the “magic bullet drug” almost 100 years ago, cell- modified with synthetic cell-specific peptides to redirect
specific targeting of therapeutic molecules remains a the native tropism. However, there are drawbacks to
major challenge in biomedicine. Most efforts toward this this approach, including the requirement for a great deal
goal have focused on exploiting monoclonal antibodies of experimental optimization. Thus, this is not a conve-
that recognize well-characterized cell surface antigens nient method for rapid validation of phage clones iso-
as cell-homing reagents. While the use of monoclonal lated from phage display selections.
antibodies as delivery reagents has the advantage of In this issue of Chemistry & Biology, Arap and Pasqua-
high affinity and specificity, the approach suffers from lini report the construction of a chimeric phage that can
certain limitations, such as nonspecific uptake by the easily be modified for the delivery of a wide variety of
reticuloendothelial system, high production costs, and reagents [1]. Taking advantage of established methods
difficulty in modifying these macromolecules to deliver to display foreign peptides on the surface of filamentous
active therapeutics. bacteriophage, the group genetically engineered a M13
To overcome the limitations of antibodies, chemists bacteriophage derivative to display a cell-targeting pep-
and biologists have turned to peptides as targeting tide on the pIII minor coat protein, as well as a biotin-
agents [2, 3]. Phage display libraries have proven to be like peptide on the pVIII major coat protein (Figure 1). The
a rich source of cell-targeting peptides. Phage panning cell targeting peptide is a well-characterized double-cyclic
on cell surface receptors [4, 5], cells in culture [6–12], peptide comprised of the sequence CDRGDCFC and is
and in whole animals [13–16] has yielded peptides that referred to as RGD-4C. RGD-4C was originally selected
bind cells with good affinities. More importantly, many
from a phage panning experiment using the v3 integrinof the isolated peptides display specificity for the target
as bait [4] and was again selected in an in vivo panning
cell type, indicating that they may be useful reagents
experiment to isolate peptides that target the vascula-
for clinical applications.
ture of breast tumors [19]. Subsequently, RGD-4C wasBiopanning on intact cells in culture or in whole ani-
shown to bind to v integrins and consequently selectivelymals has the important advantage that it requires no
home toward several different types of tumors dis-prior knowledge of any cell-specific receptor. Thus, pep-
playing this integrin subunit [20]. The biotin-mimetictides can be isolated that target poorly characterized
peptide used by the Pasqualini group contains the strep-cell types, where little is known about their cell surface
tavidin binding motif HPQ and is displayed on approxi-protein profile. Pasqualini and coworkers have pion-
mately 4%–8% of the pVIII proteins on the phage sur-eered the use of in vivo panning to isolate organ homing
face. The authors demonstrate that the hybrid phagephage from peptide libraries [13]. In summary, with this
retains its affinity for both its cellular target, v, andmethod phage libraries are injected into the tail vein of
streptavidin.mice. After a short incubation time, the mice are sacri-
Addition of the biotin-like tag to the phage scaffoldficed, and the target organs of interest are removed.
allows for the phage to be characterized in several differ-The organ-associated phage are retrieved and amplified
ent applications without further chemical modification.from the homogenized tissue, and the panning is re-
In this report, the authors demonstrate that the chimericpeated in another mouse using the isolated phage pool.
phage can be attached to a streptavidin-coated solidAfter 3–5 sequential rounds of panning, among the iso-
support (plates or magnetic beads) and used to capturelated organ-specific peptides, several peptide motifs are
v-expressing cells. Phage that express only the RDG-typically identified for a given organ. Using this protocol,
4C peptide or the biotin-like peptide alone could notphage have been isolated that target the vasculature of
successfully capture and retainv-expressing cells, indi-many different tissue types as well as different tumors
cating that the phage binds to the solid support through[13–16]. This group has recently reported progress to-
the biotin-mimetic peptide, and the RGD-4C peptide isward isolating peptides that home to vasculature beds
responsible for cell binding. Furthermore, the authorsin humans as well [17].
demonstrate that the biotin peptide can be used in aOnce a phage clone that targets the desired cell type
similar fashion to biotin in cell-staining experiments.has been isolated, the next challenge faced by research-
ers is to utilize it for delivering active biomolecules, such To visualize phage binding in their study, chimeric phage
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Figure 1. Graphic Representation of a Bi-
functional Cell-Targeting Bacteriophage
were incubated with cells followed by subsequent incu- many different assays to be performed without the need
for chemical conjugation or the creation of new re-bation with streptavidin-coated fluorescent micro-
agents. While other chimeric phage have been createdspheres. The fluorescent streptavidin beads bound the
[21, 22], none have been so thoroughly characterizedbiotin peptide-labeled phage, illuminating cells with
and have the broad applications of this construct. Thebound phage particles. Cell-targeting hybrid phage can
power of this type of phage construct is its utility foralso be utilized to deliver fluorescent nanoparticles in
rapidly validating of phage clones isolated from librarya cell-specific fashion. The authors demonstrated this
selections. Creating chimeric phage library in whichby conjugating chimeric phage to streptavidin-coated
members of a peptide library are expressed on pIII andquantum dots via the biotin peptide. The nanoparticle
the biotin peptide on pVIII will allow for rapid selectionwas successfully delivered to the cytoplasm of cells
and characterization of phage clones. While there willexpressing v integrins; thus, not only is the phage in-
certainly continue to be efforts placed on translating theternalized, but it can deliver cargo as well. Lastly, the
translating peptides out of the context of phage to bechimeric phage was utilized in a surface plasmon reso-
used as small molecule delivery reagents, this dual-nance assay to determine cell binding. Streptavidin-
function phage will allow the peptide leads to be pre-coated biosensor chips were coated with the hybrid
screened as delivery reagents before further develop-phage, and target cells were passed over the sensor to
ment as potential therapeutics.detect cell binding over time. Consistent with earlier
experiments, only background binding was observed
when no phage is added to the sensor chip, and the
Kathlynn C. Brownrate of cell mass buildup is significantly greater than
Center for Biomedical Inventionswhen the control phage is used. In summary, addition
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